全文获取类型
收费全文 | 4461篇 |
免费 | 459篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 118篇 |
妇产科学 | 137篇 |
基础医学 | 364篇 |
口腔科学 | 119篇 |
临床医学 | 537篇 |
内科学 | 989篇 |
皮肤病学 | 182篇 |
神经病学 | 197篇 |
特种医学 | 433篇 |
外国民族医学 | 1篇 |
外科学 | 554篇 |
综合类 | 241篇 |
一般理论 | 2篇 |
预防医学 | 637篇 |
眼科学 | 53篇 |
药学 | 142篇 |
中国医学 | 1篇 |
肿瘤学 | 196篇 |
出版年
2023年 | 50篇 |
2021年 | 39篇 |
2020年 | 54篇 |
2018年 | 74篇 |
2017年 | 52篇 |
2016年 | 65篇 |
2015年 | 81篇 |
2014年 | 141篇 |
2013年 | 204篇 |
2012年 | 121篇 |
2011年 | 157篇 |
2010年 | 144篇 |
2009年 | 131篇 |
2008年 | 145篇 |
2007年 | 177篇 |
2006年 | 145篇 |
2005年 | 139篇 |
2004年 | 144篇 |
2003年 | 107篇 |
2002年 | 105篇 |
2001年 | 94篇 |
2000年 | 105篇 |
1999年 | 115篇 |
1998年 | 95篇 |
1997年 | 112篇 |
1996年 | 97篇 |
1995年 | 83篇 |
1994年 | 83篇 |
1993年 | 69篇 |
1992年 | 108篇 |
1991年 | 107篇 |
1990年 | 119篇 |
1989年 | 136篇 |
1988年 | 116篇 |
1987年 | 96篇 |
1986年 | 112篇 |
1985年 | 114篇 |
1984年 | 77篇 |
1983年 | 55篇 |
1982年 | 57篇 |
1981年 | 46篇 |
1979年 | 43篇 |
1978年 | 37篇 |
1977年 | 43篇 |
1976年 | 52篇 |
1975年 | 49篇 |
1973年 | 41篇 |
1972年 | 46篇 |
1971年 | 40篇 |
1967年 | 35篇 |
排序方式: 共有4943条查询结果,搜索用时 0 毫秒
91.
J W Winslow A Shih J H Bourell G Weiss B Reed J T Stults L T Goldsmith 《Endocrinology》1992,130(5):2660-2668
Unlike that of other species, which have only one gene encoding relaxin, the human genome contains two nonallelic genes for relaxin, designated H1 and H2, which encode markedly different relaxin peptides. Whereas human relaxin gene H2 is selectively expressed in the ovary, no ovarian expression of gene H1 has been detected. Since relaxin is actively produced in the human male, it is possible to postulate divergent gene expression of relaxin in the male and female. We examined this question directly through the structural determination of human seminal relaxin and its comparison with the structure of human luteal relaxin. Partially purified relaxin, prepared from pooled human seminal plasma which had been delipidated by extraction with acid acetone and hexane, subjected to two cycles of HPLC and an additional purification step by ion-exchange chromatography, was further purified by immunoaffinity chromatography, using a monoclonal antibody to the H2 relaxin A chain which cross-reacts with synthetic H1 relaxin, followed by an additional HPLC step performed on a C4 reverse-phase column. The recovered, purified relaxin was then analyzed by N-terminal gas-phase sequencing and fast atom bombardment mass spectroscopy for determination of the amino acid sequence and molecular ions of the A and B chains, respectively. The results demonstrate that the structure of the predominant relaxin in human semen plasma is derived from the product of the H2 gene, consisting of a N-terminal pyroglutamic acid A-24 A chain and a mixture of B-26 and B-27 B chains. With the exception of degradation of the seminal relaxin B chain C-terminus, this structure is identical to the structure of human luteal relaxin. Therefore, both human seminal and luteal relaxin are products of the H2 gene. 相似文献
92.
This paper describes the design of a double infusion microtube and its use to directly observe the aggregation of platelets undergoing Poiseuille flow immediately after the introduction of 1 μM ADP. Citrated human platelet-rich plasma flowed between two reservoirs through a 100-μm-diameter flow tube at the entrance of which ADP was simultaneously infused through the tip of a concentrically located micropipet. With the aid of microcinematography, the time course of platelet aggregation was followed by measuring the number distribution of single cells and aggregates across the median plane of the tube at various distances downstream of the micropipet. Preliminary studies covering a range of mean tube shear rates from 2 to 30 sec?1 showed that, for a given donor, the fraction of platelets in aggregates, both in control runs (infusion of Tyrodes) and in experimental runs (infusion of ADP) was reproducible to within ± 1%. Except at the lowest shear rate, the extent of aggregation increased with increasing distance down the tube. 相似文献
93.
94.
Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics 总被引:7,自引:0,他引:7 下载免费PDF全文
Voutetakis A Kok MR Zheng C Bossis I Wang J Cotrim AP Marracino N Goldsmith CM Chiorini JA Loh YP Nieman LK Baum BJ 《Proceedings of the National Academy of Sciences of the United States of America》2004,101(9):3053-3058
The use of critical-for-life organs (e.g., liver or lung) for systemic gene therapeutics can lead to serious safety concerns. To circumvent such issues, we have considered salivary glands (SGs) as an alternative gene therapeutics target tissue. Given the high secretory abilities of SGs, we hypothesized that administration of low doses of recombinant adeno-associated virus (AAV) vectors would allow for therapeutic levels of transgene-encoded secretory proteins in the bloodstream. We administered 10(9) particles of an AAV vector encoding human erythropoietin (hEPO) directly to individual mouse submandibular SGs. Serum hEPO reached maximum levels 8-12 weeks after gene delivery and remained relatively stable for 54 weeks (longest time studied). Hematocrit levels were similarly increased. Moreover, these effects proved to be vector dose-dependent, and even a dosage as low as 10(8) particles per animal led to significant increases in hEPO and hematocrit levels. Vector DNA was detected only within the targeted SGs, and levels of AAV copies within SGs were highly correlated with serum hEPO levels (r = 0.98). These results show that SGs appear to be promising targets with potential clinical applicability for systemic gene therapeutics. 相似文献
95.
96.
Lisa Mosconi Juha O. Rinne Wai H. Tsui John Murray Yi Li Lidia Glodzik Pauline McHugh Schantel Williams Megan Cummings Elizabeth Pirraglia Stanley J. Goldsmith Shankar Vallabhajosula Noora Scheinin Tapio Viljanen Kjell Någren Mony J. de Leon 《Neurobiology of aging》2013
This study examines the relationship between fibrillar beta-amyloid (Aβ) deposition and reduced glucose metabolism, a proxy for neuronal dysfunction, in cognitively normal (NL) individuals with a parent affected by late-onset Alzheimer's disease (AD). Forty-seven 40–80-year-old NL received positron emission tomography (PET) with 11C-Pittsburgh compound B (PiB) and 18F-fluoro-2-deoxy-d-glucose (FDG). These included 19 NL with a maternal history (MH), 12 NL with a paternal history (PH), and 16 NL with negative family history of AD (NH). Automated regions of interest, statistical parametric mapping, voxel-wise intermodality correlations, and logistic regressions were used to examine cerebral-to-cerebellar PiB and FDG standardized uptake value ratios across groups. The MH group showed higher PiB retention and lower metabolism in AD regions compared with NH and PH, which were negatively correlated in posterior cingulate, frontal, and parieto-temporal regions (Pearson r ≤ −0.57, p ≤ 0.05). No correlations were observed in NH and PH. The combination of Aβ deposition and metabolism yielded accuracy ≥ 69% for MH vs. NH and ≥ 71% for MH vs. PH, with relative risk = 1.9–5.1 (p values < 0.005). NL individuals with AD-affected mothers show co-occurring Aβ increases and hypometabolism in AD-vulnerable regions, suggesting an increased risk for AD. 相似文献
97.
Stephanie R McKeown Paul Hatfield Robin JD Prestwich Richard E Shaffer Roger E Taylor 《The British journal of radiology》2015,88(1056)
Most radiotherapy (RT) involves the use of high doses (>50 Gy) to treat malignant disease. However, low to intermediate doses (approximately 3–50 Gy) can provide effective control of a number of benign conditions, ranging from inflammatory/proliferative disorders (e.g. Dupuytren''s disease, heterotopic ossification, keloid scarring, pigmented villonodular synovitis) to benign tumours (e.g. glomus tumours or juvenile nasopharyngeal angiofibromas). Current use in UK RT departments is very variable. This review identifies those benign diseases for which RT provides good control of symptoms with, for the most part, minimal side effects. However, exposure to radiation has the potential to cause a radiation-induced cancer (RIC) many years after treatment. The evidence for the magnitude of this risk comes from many disparate sources and is constrained by the small number of long-term studies in relevant clinical cohorts. This review considers the types of evidence available, i.e. theoretical models, phantom studies, epidemiological studies, long-term follow-up of cancer patients and those treated for benign disease, although many of the latter data pertain to treatments that are no longer used. Informative studies are summarized and considered in relation to the potential for development of a RIC in a range of key tissues (skin, brain etc.). Overall, the evidence suggests that the risks of cancer following RT for benign disease for currently advised protocols are small, especially in older patients. However, the balance of risk vs benefit needs to be considered in younger adults and especially if RT is being considered in adolescents or children. 相似文献
98.
Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe 下载免费PDF全文
JR Santos A Cozzi‐Lepri A Phillips S De Wit C Pedersen P Reiss A Blaxhult A Lazzarin M Sluzhynska C Orkin C Duvivier J Bogner P Gargalianos‐Kakolyris P Schmid G Hassoun I Khromova M Beniowski V Hadziosmanovic D Sedlacek R Paredes JD Lundgren 《HIV medicine》2018,19(5):324-338
Objectives
The aim of the study was to evaluate the long‐term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)‐, darunavir/ritonavir (DRV/r)‐, and lopinavir/ritonavir (LPV/r)‐containing regimens.Methods
Data were analysed for 5678 EuroSIDA‐enrolled patients starting a DRV/r‐, ATZ/r‐ or LPV/r‐containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART‐naïve subjects (8%) at ritonavir‐boosted protease inhibitor (PI/r) initiation; (2) ART‐experienced individuals (44%) initiating the new PI/r with a viral load (VL) ≤500 HIV‐1 RNA copies/mL; and (3) ART‐experienced patients (48%) initiating the new PI/r with a VL >500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements >200 copies/mL ≥24 weeks after PI/r initiation. Kaplan–Meier and multivariable Cox models were used to compare risks of failure by PI/r‐based regimen. The main analysis was performed with intention‐to‐treat (ITT) ignoring treatment switches.Results
The time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log‐rank test; P < 0.02) in all analyses. Nevertheless, the risk of VF in ART‐naïve patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment‐experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r‐based ART.Conclusions
Although confounding by indication and calendar year cannot be completely ruled out, in ART‐experienced subjects the long‐term effectiveness of DRV/r‐containing regimens appears to be greater than that of ATZ/r and LPV/r.99.
Plasma vitamin D metabolite concentrations in chronic renal failure: effect of oral administration of 25-hydroxyvitamin D3 总被引:3,自引:0,他引:3
B P Halloran P Schaefer M Lifschitz M Levens R S Goldsmith 《The Journal of clinical endocrinology and metabolism》1984,59(6):1063-1069
The circulating concentrations of 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D are abnormally low in patients with chronic renal failure (CRF). To determine the importance of substrate (25-hydroxyvitamin D) concentration in this phenomenon, five patients with end stage renal disease treated with hemodialysis were given 25-hydroxyvitamin D3 (25-OH-D3) orally for 4 weeks. The serum concentration of 25-OH-D3 increased from a mean (+/- SEM) of 26 +/- 5 ng/ml immediately before therapy to a maximum of 108 +/- 5 ng/ml 4 weeks after beginning administration of 25-OH-D3. The concentrations of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 24,25-dihydroxyvitamin D3 (24,25(OH)2D3), and 25,26-dihydroxyvitamin D3 (25,26(OH)2D3) increased from 6.6 +/- 0.8 pg/ml, 0.29 +/- 0.10 ng/ml, and 0.36 +/- 0.06 ng/ml, respectively, immediately before 25-OH-D3 administration to 21.7 +/- 2.2 pg/ml, 0.48 +/- 0.09 ng/ml; and 0.78 +/- 0.12 ng/ml, respectively, after 4 weeks of administration of 25-OH-D3. These results suggest that substrate availability may be an important determinant of the circulating concentrations of these metabolites in patients with CRF. It seems possible that the therapeutic effects of 25-OH-D3 administration to the CRF patient may be mediated through the normal actions of 1,25-dihydroxyvitamin D3, 24,25-dihydroxyvitamin D3, and perhaps other metabolites rather than through analog effects of 25-OH-D3. 相似文献
100.